

PRESS RELEASE

Caen, France, January 6th 2025

H.A.C. Pharma announces the acquisition from Eisai Co., Limited of the European and UK rights to the drug product TARGRETIN®

The French pharmaceutical company H.A.C. Pharma boosts its growth strategy in Europe and strengthens its portfolio of drugs with significant therapeutic added value through the acquisition of the European and UK rights to the hematology specialty product TARGRETIN® (bexarotene) from Eisai Co., Limited.

TARGRETIN®, active ingredient bexarotene, is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous T-cell lymphoma (CTCL). CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin. TARGRETIN® is used in patients who have an advanced disease and have had at least one other treatment.

H.A.C. Pharma offers patients a diversified portfolio of essential medicines, orphan drugs and life-saving treatments. The group focuses its efforts in three priority therapeutic areas: onco-hematology, central nervous system and endocrinology.

H.A.C. Pharma is recognized for its support to patients in the diagnosis and understanding of their illness, its treatment and therapeutic compliance. To achieve this, H.A.C. Pharma develops new formulations together with compliance tools and deploys a Medical Science Liaison Team to promote the proper use of its medicines. H.A.C. Pharma also directly manages the continuous supply of its product portfolio and leads a pan-European network of distributors.

Along with the founder and majority shareholder Philippe Bissay, the new management team has implemented an intensive search for product acquisitions and in-licensing to expand its portfolio and footprint in Europe and the UK. Supported by Turenne Santé and BNPP Développement, which acquired a stake in the company in January 2022, H.A.C. Pharma wishes to continue expanding its range of products and territories.

Philippe Bissay, Chairman and CEO of H.A.C. Pharma, declares: *“We are honored by Eisai’s Team trust and confidence in H.A.C. Pharma.*

This major acquisition is the second this year, along with very promising in licensing deals and partnerships with international healthcare companies. It rewards the intensive work of our teams and validates our development strategy in Europe, based on the acquisition of proven molecules and the launch of innovative products under license. It is also the result of a close collaboration with our banks: BNP, Arkéa, Caisse d’Epargne, BPI and our financial partner Eiffel.”

Mounia Chaoui and Sophie Canetos, Turenne Santé, indicate: *“We are delighted with this second acquisition. This product strengthens H.A.C. Pharma’s positioning in a therapeutic indication that it knows well. We want to continue and significantly expand H.A.C. Pharma product portfolio.”*

Frédéric Connault, BNP PARIBAS Développement, adds: *“We are very pleased with this acquisition, a major step in the transformation of H.A.C. Pharma into a key European player in hospital and specialty prescription drugs. We wish to continue our efforts in this direction.”*

PRESS CONTACTS

Delphine Granier – Turenne Groupe

dgranier@turennecapital.com

+33 6 33 05 48 50

H.A.C. Pharma

communication@hacpharma.com

+33 2 31 47 92 46

ABOUT H.A.C. PHARMA

H.A.C. Pharma is a French independent pharmaceutical laboratory based in Caen. Founded in 2007 by Philippe Bissay, H.A.C. Pharma works to maintain and make available drugs with significant therapeutic added value. H.A.C. Pharma markets prescription drugs in Europe, in various therapeutic areas such as onco-hematology, neurology, psychiatry and endocrinology.

Health actor, present alongside patients and health professionals, H.A.C. Pharma is recognized for promoting the proper use of its pharmaceutical specialties.

H.A.C. Pharma is pursuing its growth strategy in Europe via three areas of development: collaboration with international laboratories for the marketing of their drugs, the acquisition of mature molecules and the launch of innovative products under license.

www.hacpharma.com/en/

ABOUT TURENNE GROUPE

Independent leader in small cap private equity in France, Turenne Groupe has been supporting entrepreneurs for 25 years, via its management companies, in their innovation, development and transfer projects of their company throughout the country.

With nearly 2 billion euros in assets under management and +300 companies in its portfolio, Turenne Groupe relies on sectoral expertise with dedicated teams in the health, engineering and environmental services sectors. , deeptech, hotels, as well as specific expertise (debt funds and funds with reinforced CSR criteria).

Present throughout France with 7 regional locations (Paris, Lille, Lyon, Marseille, Nice, Bordeaux and Nantes) and regional funds, Turenne Groupe has 85 employees, half of whom are in the region.

A mission-driven company since 2023, and 100% owned by its employees, Turenne Groupe actively supports its portfolio companies in their CSR approach by strongly promoting the sharing of value creation. Turenne Groupe also finances and runs the Béatrice Denys Foundation for therapeutic innovation.

www.turennecapital.com

ABOUT BNP PARIBAS DEVELOPPEMENT

BNP Paribas Développement, an independent subsidiary of the international banking group BNP Paribas, is a public limited company which has, for over 30 years, invested its own funds directly as a minority shareholder to support the development of successful SMEs & ETIs and ensure their sustainability by facilitating their transmission. Beyond the financial resources made available to the company to ensure stable resources, the vocation of BNP Paribas Développement is to support the management team over the long term in carrying out its medium-term strategic projects. Our minority positioning ensures our partners appropriate governance without interference in day-to-day management, while benefiting from the strength of a recognized group and the experience of a partner with a portfolio of more than 400 diversified holdings representing more than of €2000 million invested.